Matches in SemOpenAlex for { <https://semopenalex.org/work/W3217272311> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W3217272311 endingPage "vi97" @default.
- W3217272311 startingPage "vi97" @default.
- W3217272311 abstract "Abstract Wild-type IDH glioblastoma (wtGBM) represents ≥90% of human GBM patient diagnoses with a median age of onset at 68-70 years of age. We previously found a decline of GBM patient survival with progressive age and that subjects ≥65 years of age had the poorest prognosis. We also showed an age-dependent enhancement of immune suppression in the brain that negatively affected immunotherapeutic efficacy in older adult mice with syngeneic brain tumors. Here, we extended those observations while studying C57BL/6 mice with intracranial CT-2A or GL261 between 80-110 weeks old - analogous to the age of a wtIDH GBM patient diagnosis. Overall survival of older adult mice with CT-2A or GL261 was significantly decreased when subjects were lymphopenic for CD4+ T cells as compared to an IgG Ab treatment group (n=12/group; p< 0.01). CD8+ T cell or NK cell leukopenia had no effect on survival outcomes. The negative effect of CD4+ T cell lymphopenia in older adults was not observed in younger mice with brain tumors. We also investigated the increased immunosuppression in the brain and its relationship to the accumulation of senescent cells and the treatment with standard of care radiation/temozolomide (RT/TMZ). p16INK4A, a marker for senescent cells, was increased in non-tumor cells of the brain during advanced age and its expression was increased after treatment with RT/TMZ. Older adult mice with brain tumors and treated with senolytics showed decreased p16INK4A levels after treatment with RT/TMZ. Senolytic treatment also improved the efficacy of combination therapy with RT, anti-PD-1 mAb, and IDO enzyme inhibitor in older adults as compared to senolytics alone or the triple immunotherapeutic cocktail alone (n=12-15/group; p< 0.01). Collectively, the results suggest that strategies aimed at reversing the effects of the aging combined with tumor eradication therapies may be particularly beneficial for older adult human patients with GBM." @default.
- W3217272311 created "2021-12-06" @default.
- W3217272311 creator A5019501470 @default.
- W3217272311 creator A5023866306 @default.
- W3217272311 creator A5048556371 @default.
- W3217272311 creator A5050603971 @default.
- W3217272311 creator A5074788911 @default.
- W3217272311 creator A5074800269 @default.
- W3217272311 creator A5082027834 @default.
- W3217272311 date "2021-11-02" @default.
- W3217272311 modified "2023-10-16" @default.
- W3217272311 title "IMMU-24. IMPROVING OUTCOMES IN OLDER ADULTS WITH GLIOBLASTOMA BY REVERSING AGE-RELATED CHANGES" @default.
- W3217272311 doi "https://doi.org/10.1093/neuonc/noab196.383" @default.
- W3217272311 hasPublicationYear "2021" @default.
- W3217272311 type Work @default.
- W3217272311 sameAs 3217272311 @default.
- W3217272311 citedByCount "0" @default.
- W3217272311 crossrefType "journal-article" @default.
- W3217272311 hasAuthorship W3217272311A5019501470 @default.
- W3217272311 hasAuthorship W3217272311A5023866306 @default.
- W3217272311 hasAuthorship W3217272311A5048556371 @default.
- W3217272311 hasAuthorship W3217272311A5050603971 @default.
- W3217272311 hasAuthorship W3217272311A5074788911 @default.
- W3217272311 hasAuthorship W3217272311A5074800269 @default.
- W3217272311 hasAuthorship W3217272311A5082027834 @default.
- W3217272311 hasBestOaLocation W32172723111 @default.
- W3217272311 hasConcept C126322002 @default.
- W3217272311 hasConcept C142724271 @default.
- W3217272311 hasConcept C143998085 @default.
- W3217272311 hasConcept C167672396 @default.
- W3217272311 hasConcept C203014093 @default.
- W3217272311 hasConcept C205545832 @default.
- W3217272311 hasConcept C2777389519 @default.
- W3217272311 hasConcept C2778227246 @default.
- W3217272311 hasConcept C2779056147 @default.
- W3217272311 hasConcept C2779130545 @default.
- W3217272311 hasConcept C2780252810 @default.
- W3217272311 hasConcept C502942594 @default.
- W3217272311 hasConcept C509974204 @default.
- W3217272311 hasConcept C71924100 @default.
- W3217272311 hasConcept C8891405 @default.
- W3217272311 hasConceptScore W3217272311C126322002 @default.
- W3217272311 hasConceptScore W3217272311C142724271 @default.
- W3217272311 hasConceptScore W3217272311C143998085 @default.
- W3217272311 hasConceptScore W3217272311C167672396 @default.
- W3217272311 hasConceptScore W3217272311C203014093 @default.
- W3217272311 hasConceptScore W3217272311C205545832 @default.
- W3217272311 hasConceptScore W3217272311C2777389519 @default.
- W3217272311 hasConceptScore W3217272311C2778227246 @default.
- W3217272311 hasConceptScore W3217272311C2779056147 @default.
- W3217272311 hasConceptScore W3217272311C2779130545 @default.
- W3217272311 hasConceptScore W3217272311C2780252810 @default.
- W3217272311 hasConceptScore W3217272311C502942594 @default.
- W3217272311 hasConceptScore W3217272311C509974204 @default.
- W3217272311 hasConceptScore W3217272311C71924100 @default.
- W3217272311 hasConceptScore W3217272311C8891405 @default.
- W3217272311 hasIssue "Supplement_6" @default.
- W3217272311 hasLocation W32172723111 @default.
- W3217272311 hasOpenAccess W3217272311 @default.
- W3217272311 hasPrimaryLocation W32172723111 @default.
- W3217272311 hasRelatedWork W165245056 @default.
- W3217272311 hasRelatedWork W2032981778 @default.
- W3217272311 hasRelatedWork W2094900768 @default.
- W3217272311 hasRelatedWork W2150741177 @default.
- W3217272311 hasRelatedWork W2358125876 @default.
- W3217272311 hasRelatedWork W2360323568 @default.
- W3217272311 hasRelatedWork W2518228060 @default.
- W3217272311 hasRelatedWork W3029090213 @default.
- W3217272311 hasRelatedWork W3163963294 @default.
- W3217272311 hasRelatedWork W3217464727 @default.
- W3217272311 hasVolume "23" @default.
- W3217272311 isParatext "false" @default.
- W3217272311 isRetracted "false" @default.
- W3217272311 magId "3217272311" @default.
- W3217272311 workType "article" @default.